Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adeona Pharmaceuticals has reported that the ongoing clinical trial of its Trimesta (oral estriol) drug candidate has received an additional $860,440 in grant funding through the American Recovery and Reinvestment Act. The current phase II/III clinical study is a double-blind, placebo-controlled trial taking place at 16 sites in the US and is expected to enroll up to 150 female multiple sclerosis patients.
Subscribe to our email newsletter
The study is being conducted by Dr. Rhonda Voskuhl, director of UCLA Multiple Sclerosis Program, UCLA Department of Neurology.
Investigators will administer Trimesta along with glatimer acetate (Copaxone), an FDA approved therapy for MS, to women between the ages of 18-50 who have been recently diagnosed with relapsing-remitting multiple sclerosis, said the company.
The ongoing clinical trial previously received a $5m grant from the National Multiple Sclerosis Society (NMSS), in partnership with the National MS Society’s Southern California chapter, with support from the National Institutes of Health (NIH).
Dr. Voskuhl said: “This additional funding has already had a positive impact on our trial. It has increased the rate of enrollment by supporting the addition of 9 more clinical sites, bringing the total up to 16 sites across the US. We were pleased that our trial was deemed important enough to be supplemented with these additional funds.”